Related Experiment Video
Updated: Jun 21, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
Longitudinal study of beta2-microglobulin abnormalities in schizophrenia
Seetharamaiah Chittiprol1, Ganesan Venkatasubramanian, Narendran Neelakantachar
1Department of Neurochemistry, National Institute of Mental Health and Neurosciences, Bangalore, India.
Abstract:
In an earlier cross-sectional study, we reported antipsychotic-naive schizophrenia patients to have significantly elevated beta2-microglobulin (beta2M) level suggestive of its potential association with the pathogenesis of schizophrenia. In this study, we present the follow-up analyses of beta2M in 31 patients from the previous study who were re-assessed after 92.1+/-7.2 days of antipsychotic treatment. Compared to baseline, there was a further significant elevation of beta2M in schizophrenia patients following treatment, especially in those who were treated with risperidone. Also, there was a significant negative correlation between beta2M level and total psychopathology score during follow-up in risperidone group. The study findings extend further support the role for beta2M in the pathogenesis of schizophrenia strengthening the case for immune dysregulation. Moreover, the observations suggest the possibility that the mechanism of action of antipsychotics might involve alteration of immune parameters.
Insights
Antipsychotic treatment further elevated beta2-microglobulin (beta2M) levels in schizophrenia patients, suggesting immune dysregulation in the disorder. Risperidone treatment showed a notable increase in beta2M and a correlation with reduced psychopathology.
Area of Science:
- Neuroscience
- Immunology
- Psychiatry
Background:
- Previous cross-sectional study indicated elevated beta2-microglobulin (beta2M) in antipsychotic-naive schizophrenia patients.
- This elevation suggested a potential link between beta2M and schizophrenia pathogenesis.
Purpose of the Study:
- To investigate the longitudinal changes in beta2-microglobulin (beta2M) levels in schizophrenia patients undergoing antipsychotic treatment.
- To explore the relationship between beta2M levels and psychopathology during treatment.
Main Methods:
- Follow-up analysis of 31 schizophrenia patients from a previous cross-sectional study.
- Re-assessment of beta2M levels after approximately 92 days of antipsychotic treatment.
- Correlation analysis between beta2M levels and total psychopathology scores.
Main Results:
- A significant further elevation in beta2M levels was observed post-treatment compared to baseline.
- Risperidone treatment group showed a particularly significant increase in beta2M.
- A significant negative correlation was found between beta2M levels and psychopathology scores in the risperidone group.
Conclusions:
- Findings support the role of beta2-microglobulin (beta2M) in schizophrenia pathogenesis and immune dysregulation.
- Observations suggest antipsychotic mechanisms may involve modulation of immune parameters.
- Further research into the interplay between immune markers and antipsychotic efficacy is warranted.
Related Concept Videos
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Psychological and Sociocultural Causes of Schizophrenia
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Longitudinal Studies
Longitudinal Research
